Payment overview · 2025
General Payments
$217.48
12 reported records · 8 companies
Healthcare provider profile · identity verified
Gary Allan Curran, MD
Allopathic & Osteopathic Physicians|Family Medicine · ARDEN, NC · NPI 1346225232
Verified facts
What the public records show
CMS Open Payments records show Gary Allan Curran, MD received $217.48 in general payments during 2025 across 12 reported records.
ABBVIE INC. accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.45 | 24.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $40.04 | 18.4% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $36.09 | 16.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.34 | 11.2% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.47 | 8.5% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.16 | 7.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.23 | 6.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.70 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $217.48 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $40.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.61 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.34 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
| NEXIUM Normalized: nexium |
Drug | AstraZeneca Pharmaceuticals LP | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 14 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 18 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
18 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 252 | 76 |
| Levothyroxine Sodium | Levothyroxine Sodium | 241 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 241 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 238 | 73 |
| Atorvastatin Calcium | Atorvastatin Calcium | 215 | 60 |
| Losartan Potassium | Losartan Potassium | 194 | 54 |
| Lisinopril | Lisinopril | 167 | 57 |
| Omeprazole | Omeprazole | 163 | 55 |
| Metformin Hcl | Metformin Hcl | 137 | 35 |
| Tramadol Hcl | Tramadol Hcl | 131 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 128 | 17 |
| Gabapentin | Gabapentin | 115 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 107 | 19 |
| Simvastatin | Simvastatin | 104 | 36 |
| Lorazepam | Lorazepam | 90 | 14 |
| Furosemide | Furosemide | 87 | 28 |
| Eliquis | Apixaban | 83 | 13 |
| Famotidine | Famotidine | 75 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 74 | 26 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | 17 |
| Ozempic | Semaglutide | 64 | suppressed |
| Allopurinol | Allopurinol | 63 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 63 | 15 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 18 |
| Trazodone Hcl | Trazodone Hcl | 61 | 20 |
| Prednisone | Prednisone | 59 | 28 |
| Sertraline Hcl | Sertraline Hcl | 56 | 20 |
| Alprazolam | Alprazolam | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 53 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 15 |
| Ipratropium Bromide | Ipratropium Bromide | 44 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 42 | 15 |
| Metformin Hcl Er | Metformin Hcl | 40 | 16 |
| Glipizide | Glipizide | 39 | 11 |
| Spironolactone | Spironolactone | 35 | 14 |
| Finasteride | Finasteride | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 14 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 31 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Xarelto | Rivaroxaban | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 15 |
| Carvedilol | Carvedilol | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 11 |
| Estradiol | Estradiol | 23 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 20 | suppressed |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 19 | 19 |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 15 |
| Glimepiride | Glimepiride | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 18 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 15 |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 14 | 14 |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Insulin Lispro | Insulin Lispro | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Nitroglycerin | Nitroglycerin | 13 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | suppressed |
| Pregabalin | Pregabalin | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 12 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $217.48 · 12 records | ABBVIE INC. | AREXVY, BREZTRI, Dexcom G6 Transmitter, EVENITY, NEXIUM, QULIPTA, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error